Tenascin C (Stromal Marker For Epithelial Malignancy) Antibody - Without BSA and Azide
Mouse Monoclonal Antibody [Clone SPM319 ]
|Application ||IHC, IF, FC|
|Other Accession||3371, 143250|
|Isotype||Mouse / IgG1, kappa|
|Calculated MW||210kDa and 300kDa|
|Other Names||Tenascin, TN, Cytotactin, GMEM, GP 150-225, Glioma-associated-extracellular matrix antigen, Hexabrachion, JI, Myotendinous antigen, Neuronectin, Tenascin-C, TN-C, TNC, HXB|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Tenascin C (Stromal Marker For Epithelial Malignancy) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
In Western blotting, it reacts with two bands of ~MW of 210kDa and 300kDa, identified as two isoforms of Tenascin C. Specificity of this MAb is validated by sequential immunoprecipitation with a PAb against Tenascin C. Tenascin C is a multifunctional, disulfide-linkedĀhexameric extracellular matrix glycoprotein expressed in association with mesenchymal epithelial interactions during development and in the neo-vasculature and stroma of undifferentiated tumors. In adults, it is restricted to certain epithelial-stromal interfaces and increases markedly in hyper-proliferative diseases and in stroma of many neoplasms, including gliomas, breast, squamous and lung carcinomas.
Verstraeten AA, et. al. British Journal of Dermatology, 1992, 127(6):571-4. |
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.